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Abstract
Background: Patients with schizophrenia report muscle weakness. The relation of this muscle weakness with
performing daily life activities such as walking is however not yet studied. The aim of this study was to quantify
walking capacity and health related muscular fitness in patients with schizophrenia compared with age-, gender
and body mass index (BMI)-matched healthy controls. Secondly, we identified variables that could explain the
variability in walking capacity and in health related muscular fitness in patients with schizophrenia.
Methods: A total of 100 patients with schizophrenia and 40 healthy volunteers were initially screened. Eighty
patients with schizophrenia (36.8±10.0 years) and the 40 age-, gender- and body mass index (BMI)-matched healthy
volunteers (37.1±10.3 years) were finally included. All participants performed a standing broad jump test (SBJ) and a
six-minute walk test (6MWT) and filled out the International Physical Activity Questionnaire. Patients additionally had
a fasting metabolic laboratory screening and were assessed for psychiatric symptoms.
Results: Patients with schizophrenia did have lower 6MWT (17.9%, p<0.001) [effect size (ES)=−1.01] and SBJ (14.1%,
p<0.001) (ES=−0.57) scores. Patients were also less physically active (1291.0±1201.8 metabolic equivalent-minutes/
week versus 2463.1±1365.3, p<0.001) (ES=−0.91) than controls. Schizophrenia patients with metabolic syndrome
(MetS) (35%) had a 23.9% lower (p<0.001) SBJ-score and 22.4% (p<0.001) lower 6MWT-score than those without
MetS. In multiple regression analysis, 71.8% of the variance in 6MWT was explained by muscular fitness, BMI,
presence of MetS and physical activity participation, while 53.9% of the variance in SBJ-score was explained by age,
illness duration, BMI and physical activity participation.
Conclusions: The walking capacity and health-related muscular fitness are impaired in patients with schizophrenia
and both should be a major focus in daily clinical practice and future research.
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Patients with schizophrenia have a reduced aerobic cap-
acity [1,2] and report subjective muscle weakness [3]. It
is likely that both play an important role in the physical
adaptation to daily life activities such as walking. Previ-
ous research already demonstrated that an impaired
performance on daily life activities in patients with
schizophrenia is associated with overweight, metabolic
complications, smoking behaviour, negative symptoms
and a lower physical self-perception [4-6]. An impaired
functional walking capacity has been related as well to a
reduced health related quality of life [7].
Recently, there has been a growing interest in the
physical rehabilitation of patients with schizophrenia [8].
International guidelines state that physical activity
should be one of the cornerstones in the multidisciplin-
ary treatment [9,10]. It has been reported that physical
activity might improve glycemic control, lowers blood
pressure, improves lipid profile and decreases abdominal
fat mass [11]. Unfortunately, only 25% of patients with
schizophrenia meet the minimum health recommenda-
tions of 150 min of at least moderate intensity physical
activity per week [12] and long-term adherence to super-
vised physical activity programmes is generally poor
[11]. The failure to increase physical activity in patients
with schizophrenia has been explained by socio-demo-
graphic, somatic and motivational factors including the
presence of negative and depressive symptoms [13]. A
prerequisite for supervised physical activity programmes
in patients with schizophrenia therefore is information
about the mental and physical health status including
the presence of negative and depressive symptoms, the
magnitude of impairment in aerobic capacity and func-
tional exercise capacity and the metabolic and muscular
fitness [14].
Although a reduced muscular fitness might contribute
to daily life impairments, the extent of muscle weakness
in schizophrenia patients compared with age-, gender
and body mass index (BMI)-matched healthy subjects
and its relation with performing daily life activities such
as walking is, to the best of our knowledge, not yet
studied.
The aim of this study therefore was to quantify walk-
ing capacity and health related muscular fitness in
patients with schizophrenia compared with age-, gender
and body mass index (BMI)-matched healthy controls.
Secondly, we identified variables that could explain the
variability in walking capacity and in health related mus-
cular fitness in patients with schizophrenia.
Methods
Participants and procedure
Over a 6-month period, patients with schizophrenia of
the University Psychiatric Centre of Kortenberg and the
Brussels Nighthospital Belgium were invited to partici-
pate. Psychiatric diagnosis based on the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) criteria [15] was established by experienced
psychiatrists responsible for the patients’ treatment.
Patients were included if (a) acute symptoms were
(at least partially) remitted, and (b) patients were stable
on antipsychotic medication, i.e. using the same dosage
for at least four weeks prior to inclusion. Patients were
excluded if they had a DSM-IV diagnosis of substance
dependence. Somatic exclusion criteria included evi-
dence of significant cardiovascular, locomotor and endo-
crine disorders which, according to the American
College of Sports Medicine [16], might prevent safe
participation in the sub-maximal exercise tests. All parti-
cipants received a physical examination and baseline
electrocardiogram before testing.
Healthy control subjects were recruited among the
personnel (i.e. health care workers, researchers, stu-
dents) of the participating centres. All control subjects
were volunteers who received a general physical examin-
ation in the previous year and reported to be free of
significant psychiatric, cardiovascular, neuromuscular
and endocrine disorders that might hinder safe partici-
pation. By selection, gender distribution and mean
values for age and BMI did not differ significantly
between healthy controls and schizophrenia patients.
This matching was performed by an independent statis-
tician blinded for the physical activity and physical
fitness outcomes. All participants filled out a physical
activity questionnaire and performed afterwards a mus-
cular fitness and walk test. Participants were requested
to refrain from eating, drinking coffee or smoking during
a two-hour period prior to the tests. Patients were also
screened for psychiatric symptoms and extrapyramidal
side-effects of antipsychotic medication and received a
fasting metabolic laboratory screening.
The study procedure was approved by the Scientific
Committee of the University Psychiatric Centre of the
Catholic University of Leuven, Belgium. All participants
gave their written informed consent.
Demographical data
Demographic patients’ data (including illness duration)
were obtained from medical records while age for the
control participants was self-reported. All participants
were asked whether they currently smoked. Those parti-
cipants who responded affirmatively to this question
were asked how many cigarettes they smoked per day.
Walking capacity
The six-minute walk test (6MWT) was performed
according to the American Thoracic Society guidelines
[17] in an indoor corridor with a minimum of external
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the walkway. Participants were instructed to walk back
and forth around the cones during six minutes, without
running or jogging. Resting was allowed if necessary, but
walking was to be resumed as soon as the participants
were able to do so. The protocol stated that the testing
was to be interrupted if threatening symptoms appeared.
The total distance walked in 6 minutes was recorded to
the nearest decimetre. Standardised encouragements
were provided at recommended intervals. Supervision
and measurement of the 6MWT was performed by one
of four trained members (three physical therapists, one
research nurse). With an intra class correlation of 0.96
[95% confidence interval (CI):0.94-0.98)], the 6MWT has
been shown to be a reliable test to assess the exercise
capacity in patients with schizophrenia [18].
Health related muscular fitness
The health related muscular fitness was measured by a
standing broad jump test [19], using a tape measure on a
foam mat. Participants were asked to stand behind a line
drawn perpendicular to the tape measure and jump
forward as far as possible using arm swing and knee bend-
ing before jumping. The distance jumped was recorded
from the take-off line to the farthest point backward of
the participant. Higher scores indicate a better muscular
fitness. The standing broad jump test previously showed
an excellent reproducibility in patients with schizophrenia
with an intra class correlation of 0.98 [95% confidence
interval (CI):0.96-0.99)] [20].
Physical activity participation
The International Physical Activity Questionnaire (IPAQ)
[21] uses a structured format that asks participants to re-
call activities for each of the last seven preceding days in
morning, afternoon, and evening time periods. Data from
the IPAQ were summarised according to walking, mod-
erate (activities that take moderate physical effort and
make you breathe somewhat harder than normal such as
carrying light loads, bicycling at a regular pace, or easy
swimming), and vigorous activities (e.g., activities that
take hard physical effort and make you breathe much
harder than normal such as heavy lifting, digging, aer-
obics, or fast bicycling) per week. On the basis of what
activities participants self-reported, the interviewer also
clarified the perceived intensity of that specific activity. A
continuous indicator was calculated as a sum of weekly
metabolic equivalent (MET)-minutes per week of walk-
ing, moderate- and vigorous-intensity exercise. The MET
energy expenditure was estimated by weighting the
reported minutes per week within each activity category
by a MET energy expenditure estimate assigned to each
category of activity. MET-levels were obtained from
Ainsworth et al. [22] The weighted MET-minutes per
week were calculated as duration × frequency per week ×
MET-intensity, which were then summed across activity
domains to produce a weighted estimate of total physical
activity from all reported activities per week. Previous re-
search indicated that the IPAQ can be considered as a re-
liable surveillance tool to assess levels of PA in patients
with schizophrenia [12].
Metabolic and anthropometric measurements
Body weight was measured in light clothing to the nearest
0.1 kg using a SECA beam balance scale, and height to the
nearest 0.1 cm using a wall-mounted stadiometer. In
patients with schizophrenia a 2-hour 75-gg l u c o s el o a d
oral glucose tolerance test (OGTT) was performed accor-
ding to previously proposed guidelines [23,24]. Patients
were initiated on an overnight fast and were monitored
during the OGTT. Waist circumference (WC) was mea-
sured to nearest 1 cm at the level of the umbilicus and at
the end of expiration with the subject upright Blood pres-
sure was recorded twice in the sitting position after a five
minutes rest with an Omron M6 (HEM-7001-E) (Omron
W
Healthcare Europe). The average of both measures was
taken. Patients received a full fasting laboratory screening.
The presence of metabolic syndrome was assessed using
the International Diabetes Federation criteria [25,26]. Ac-
cording to these criteria, for a patient to be defined as
having the MetS they must have: central obesity (defined
as waist circumference ≥94 cm for Europid men and ≥80
cm for Europid women, with ethnicity specific values for
other groups) plus any two of the following four factors:
(1) raised TG level: ≥150 mg/dL (1.7 mmol/L), or specific
treatment for this lipid abnormality, (2) reduced HDL chol-
esterol: <40 mg/dL (1.03 mmol/L*) in males and <50 mg/
dL (1.29 mmol/L*) in females, or specific treatment for this
lipid abnormality, (3) raised blood pressure: systolic
BP≥130 or diastolic BP≥85 mm Hg, or treatment of previ-
ously diagnosed hypertension, (4) raised fasting plasma
glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously
diagnosed type 2 diabetes.
Psychiatric and extra-pyramidal symptoms
Psychiatric and extra-pyramidal symptoms (EPS) were
assessed by an independent and well trained nurse using
the Psychosis Evaluation tool for Common use by
Caregivers (PECC) [27]. The semi-structured PECC-inter-
view evaluates 20 symptom items on a 7-point scale.
Symptoms are grouped in 5 factors: positive, negative, de-
pressive, cognitive and excitatory symptoms. The scores
for each factor range from 4 to 28. The total score
ranges from 20 to 140. EPS scores range from 4 to 16.
Higher scores indicate more severe symptoms/side-
effects. Validation results suggest that the PECC can be
successfully used for the evaluation of these symptoms
in schizophrenia [28].
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Current antipsychotic medication use was recorded for
each patient and converted into a daily equivalent
dosage of chlorpromazine using Gardner's table [29].
Statistical analyses
Unpaired t-tests with post hoc Bonferroni correction for
continuous variables (p=0.005) and Fisher exact tests for
categorical variables (gender) (p<0.01) were used to
examine differences in characteristics between patients
and healthy controls. Additionally, we calculated effect
sizes (Cohen's d) to compare health related muscular fit-
ness, walking capacity and physical activity participation
between patients with schizophrenia and healthy con-
trols. To identify independent predictors of the walking
capacity and health related muscular fitness, a multiple
stepwise regression analysis was carried out. Significance
level was set here at p=0.01. Statistica 9 (Statsoft Inc,
Tulsa, OK, 2009) was employed for the data analyses.
Results
Participants
A total of 100 patients with schizophrenia were initially
screened. Six persons with co-morbid substance abuse
were excluded while another six patients were excluded
for a cardiovascular, locomotor or endocrine disorder
that could prevent safe participation. Of the 88 eligible
patients, another 8 declined to participate. Eighty parti-
cipants were thus included in the final analysis. No
significant differences in demographical and clinical vari-
ables were found between participants and drop-outs
(data not presented). Forty healthy controls, matched for
age, BMI and sex, agreed to participate. None of them
dropped out. Participants’ characteristics are shown in
Table 1. Sixty-five percent of the patients with schizo-
phrenia smoked compared to 25% of the healthy
controls. Smokers with schizophrenia consumed also
more cigarettes per day. Except for the fact that in
schizophrenia smokers were less physically active (MET-
minutes per week: 984.1±853.2 versus 1830.8±1517.2,
p<0.001), no statistical differences between smokers and
non-smokers were found (data not presented). Mean
duration of illness was 12.8±9.5 years. Mean daily equiva-
lent dosage of chlorpromazine was 687.2±406.0 mg/day.
Comparisons of walking capacity, health related muscular
fitness, and physical activity participation between
patients with schizophrenia and healthy controls
Patients with schizophrenia did have a significantly
impaired walking capacity (17.9%) and health related
muscular fitness (14.1%) compared to age-, gender- and
BMI-matched healthy controls (Table 2). Except for the
total minutes of walking per week, patients with schizo-
phrenia were also significantly less physically active as
measured with the IPAQ than age-, gender and BMI
matched healthy controls (Table 2).
Correlations with walking capacity and health related
muscular fitness in patients with schizophrenia
A longer distance on the standing broad jump test was
significantly correlated with a longer distance achieved
on the 6MWT (Table 3). Better performance on both
physical fitness tests was significantly associated with
lower BMI and higher physical activity levels, including
total minutes of physical activity per week, total minutes
of walking per week, total minutes of vigorous activity
per week, the sum of weekly MET-minutes per week
(Table 3). Younger age, a lower illness duration, smoking
behaviour and less negative and depressive symptoms
were only associated with a better health related muscu-
lar fitness, while a lower antipsychotic medication dose
as expressed in chlorpromazine equivalents was asso-
ciated with a higher 6MWT score (Table 3).
Differences in walking capacity and health related
muscular fitness between patients with and without
metabolic syndrome
Twenty-eight (35%) patients with schizophrenia did suffer
from the metabolic syndrome. There were no significant
differences in the presence of psychiatric symptoms or
EPS between those with and without the metabolic syn-
drome. Sixteen patients with metabolic syndrome smoked
(57.1%) compared with 24 (46.1%) in the group without
metabolic syndrome. There was no difference in the
number of cigarettes smoked per day between those with
and without the metabolic syndrome (26.8±12.2 versus
21.0±12.5, p=0.14). In contrast, the distance achieved
Table 1 Baseline characteristics of patients with
schizophrenia and healthy controls
Schizophrenia Healthy controls p
(n=80) (n=40)
Gender (M/F) 55/25 27/13 0.64
Age (years) 36.8±10.0 37.1±10.3 0.88
BMI (kg/m
2) 26.3±5.5 25.7±3.8 0.23
Smoking (cig/day) 14.8±14.8 3.8±6.7 <0.001*
PECC
Positive symptoms 8.0±4.0 /
Negative symptoms 10.4±4.5 /
Cognitive symptoms 7.0±3.6 /
Depressive symptoms 10.0±4.5 /
Excitatory symptoms 7.2±3.3 /
EPS 5.2±1.8 /
Data expressed as mean ± standard deviation, BMI=body mass index, PECC=
Psychosis evaluation tool for common use by caregivers, EPS= extra-pyramidal
symptoms, *significant after Bonferroni-correction (p=0.005).
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633.2±92.1 m, p<0.001) and the health related muscular
fitness 23.9% reduced (122.6±35.7 m versus 161.1±44.7,
p<0.001) in patients with metabolic syndrome. Patients
with metabolic syndrome walked also significantly less
minutes per week than those without metabolic syndrome
(89.8±87.9 min versus 239.4±244.5 min, p<0.001), while
their weekly energy expenditure as expressed in MET-
minutes per week (709.3±675.3 versus 1604.3±1307.7,
p<0.001) was significantly lower.
Determinants of the walking capacity in patients with
schizophrenia
Significant correlates of the 6MWT and the presence or
not of metabolic syndrome were included in a stepwise
multiple regression analysis. For physical activity partici-
pation the overall MET-minutes/week was included.
Muscular fitness, BMI, the presence of metabolic syn-
drome and physical activity participation were identified
as independent predictors of the walking capacity. The
model explained 71.8% of the variability in the distance
achieved on the 6MWT (Table 4). Almost 46% of the
variance in 6MWT could be explained by muscular
fitness alone. An additional 10.2% was explained by
BMI. MET-minutes/week and the presence of metabolic
syndrome explained 11.0% and 4.7% more of the vari-
ance. Antipsychotic medication dose could not be identi-
fied as an independent predictor.
Determinants of health related muscular fitness in
patients with schizophrenia
Except for the 6MWT score, all significant correlates for
health related muscular fitness and the presence or not
of metabolic syndrome were included in the stepwise
multiple regression analysis (Table 5). For physical activ-
ity participation the overall MET-minutes/week was
included. Age, illness duration, BMI and physical activity
participation were identified as independent predictors
Table 2 Comparisons of health related muscular fitness, walking capacity and physical activity participation between
patients with schizophrenia and healthy controls
Schizophrenia Healthy controls Δ Effect size p
n=80 n=40 Cohen’s d [95%CI]
Standing broad jump (cm) 147.4±45.4 171.7±39.4 14.1% −0.57 [−0.17 to −0.94] 0.003*
6MWT (m) 583.6±140.7 710.6±108.3 17.9% −0.97 [−0.57 to −1.37] <0.001*
IPAQ total minutes PA 326.9±306.7 563.2±293.9 41.9% −0.79 [−0.39 to −1.17] <0.001*
IPAQ total minutes of vigorous PA 36.4±81.7 88.9±88.4 59.0% −0.62 [−0.24 to −1.01] 0.003*
IPAQ total minutes of moderate PA 110.0±181.7 298.8±263.3 63.2% −0.89 [−0.49 to −1.29] 0.003*
IPAQ total minutes of walking 187.0±215.4 244.6±156.5 23.5% −0.29 [0.09 to −0.67] 0.10
IPAQ total MET-minutes/week 1291.0±1201.8 2463.1±1365.3 47.6% −0.93 [−0.53 to −1.33] <0.001*
Data expressed as number (percentage) or mean ± standard deviation. Effect sizes were calculated using Cohen’s d. Δ=the difference in % between patients and
controls, 6MWT= 6-minute walk test distance, IPAQ= International Physical Activity Questionnaire, PA=physical activity, MET= metabolic equivalent, *significant
after Bonferroni-correction (p=0.005), CI=confidence interval.
Table 3 Pearson correlations of health related muscular
fitness and walking capacity with demographic and
clinical characteristics in patients with schizophrenia
Standing broad jump 6MWT
6MWT (m) 0.68** /
Standing broad jump (cm) / 0.68**
Age (years) −0.31* −0.28
Illness duration (years) −0.53** −0.20
BMI (kg/m
2) −0.46* −0.61**
Cigarettes (cig/day) −0.32** −0.25
IPAQ total PA minutes° 0.45** 0.64**
IPAQ walking minutes° 0.37** 0.56**
IPAQ moderate PA minutes° 0.19 0.25
IPAQ vigorous PA minutes° 0.39** 0.37*
IPAQ MET-minutes/week 0.55** 0.69**
PECC Positive symptoms 0.20 0.17
PECC Negative symptoms −0.33* −0.29
PECC Depressive symptoms −0.35* −0.22
PECC Excitatory symptoms −0.10 0.15
PECC Cognitive symptoms −0.29 −0.18
Chlorpromazine equivalent −0.19 −0.42**
EPS −0.07 −0.23
*p<0.01, **p<0.001, °derived from the International Physical Activity
Questionnaire, 6MWT=6-minute walk test distance, BMI=body mass index,
IPAQ= International Physical Activity Questionnaire, PA=physical activity,
MET= metabolic equivalent, PECC= Psychosis Evaluation tool for Common use
by Caregivers, EPS=extrapyramidal side-effects.
Table 4 Multiple stepwise regression analysis of the
variables associated with the walking capacity score
Cumulative r
2 p SEE
Standing broad jump 0.459 <0.001 81.2
Body mass index 0.561 <0.001 73.7
IPAQ MET-minutes/week 0.671 <0.001 64.1
Metabolic syndrome or not 0.718 <0.001 59.8
Criteria: probability of F-to-enter ≤0.5; probability of F-to-remove ≥0.10,
r
2= determination coefficient, SEE= standard error of estimate,
IPAQ= International Physical Activity Questionnaire, MET= metabolic
equivalent, *Significance level set at p<0.01.
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explained 53.9% of the variability in the standing broad
jump score. Age explained 23.6% of the variance. An
additional 7.3% was explained by illness duration. BMI
and MET-minutes/week explained 12.4% and 10.6%
more of the variance. The presence of metabolic
syndrome, depressive and negative symptoms and smok-
ing behaviour could not be identified as independent
predictors.
Discussion
General findings
The present study demonstrates that in patients with
schizophrenia an impaired walking capacity compared to
age-, gender- and BMI-matched healthy controls is asso-
ciated with a reduced health related muscular fitness.
Older age, a longer illness duration, a higher BMI and
the current physical activity level were all identified as
independent predictors of the health related muscular
fitness.
Our data do offer more rigorous evidence for the
previously reported association in patients with psych-
otic disorders between self-reported impairments in
daily life functioning such as walking short distances and
a reduced muscle strength (i.e. handgrip strength) [30].
The present study also adds to the current knowledge
that schizophrenia patients with metabolic syndrome do
have a decreased health related muscular fitness com-
pared to those without metabolic syndrome. As was
demonstrated in the regression analysis an increased
BMI partially explains the variability in standing broad
jump scores. Patients with metabolic syndrome had an
increased BMI compared with patients without meta-
bolic syndrome. However, since healthy controls were
matched for BMI, BMI does not explain the differences
in health related muscular fitness observed between
patients and controls. Other illness-related mechanisms
might contribute to the impaired muscular fitness. Our
data demonstrate that patients with schizophrenia are at
high risk for developing metabolic complications. Body
fat, especially in the abdominal region, is a metabolically
active tissue secreting catabolic (leptin, retinol-binding
protein-4) agents [31]. The fact that next to age, illness
duration additionally explains the variance in health
related muscular fitness strengthens the hypothesis that
illness-related factors other than the investigated psychi-
atric symptoms, might contribute to the impaired mus-
cular fitness observed. However, the higher rates of
cigarettes smoking in patients with schizophrenia might
be a confounding variable. Although smoking behaviour
could not be identified as independent predictor for
health related muscular fitness in patients with schizo-
phrenia, it cannot be excluded that differences in health
related muscular fitness between patients and controls
might only reflect differences in smoking behaviour.
We also did not find any association between health
related muscular fitness, current antipsychotic medica-
tion use and EPS, which is in agreement with a previous
study reporting that those on antipsychotic drugs exhibit
the same neuromuscular pathology as drug-free patients
[32]. This might indicate that neuromuscular changes
are not related to the side-effects or the chronic course
of antipsychotic medication use. Due to the limited sam-
ple size we were however not able to investigate associa-
tions of health related muscular fitness with specific
antipsychotic agents.
Clinical implications
The present findings indicate that patients with schizo-
phrenia should improve their health related muscular
fitness in order to maintain their walking capability. The
current International Organization of Physical Therapy
in Mental Health guidelines [33] do recommend that for
substantial health benefits, patients with schizophrenia
should not only do at a minimum 150 minutes a week
of moderate-intensity, or 75 minutes of moderate-to-
vigorous-intensity aerobic activity, but should also per-
form muscle-strengthening exercises that are of at least
moderate intensity and involve all major muscle groups
on two or more days a week [33,34].
Limitations
The findings of the present study need to be interpreted
with caution because of some methodological limita-
tions. The limited sample size, especially of the healthy
controls, and the reliance on self-reported physical activ-
ity, a method that is prone to both systematic and
random errors [35], prevent us from making any firm
conclusions. Nevertheless, there was a high response
rate in the patients group which should prevent serious
distortion of the results due to selection bias. Although
in the healthy controls the IPAQ scores were in agree-
ment with several other Belgian studies [36,37], the over-
all smoking prevalence rate was approximately 1.5 times
lower than in the corresponding general population [38].
Table 5 Multiple stepwise regression analysis of the
variables associated with the health related muscular
fitness score
Cumulative r
2 p SEE
Age 0.226 <0.001* 40.3
Illness duration 0.291 <0.001* 38.6
Body mass index 0.433 <0.001* 35.2
IPAQ MET-minutes/week 0.539 <0.001* 31.9
Criteria: probability of F-to-enter ≤0.5; probability of F-to-remove ≥0.10,
r
2= determination coefficient, SEE= standard error of estimate,
IPAQ= International Physical Activity Questionnaire, MET= metabolic
equivalent, *Significance level set at p<0.01.
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volunteers cannot be excluded. Secondly, we also did
not include parameters such as socio-economic status
and educational level. Both parameters are known to be
associated with physical fitness and the level of physical
activity participation, also in patients with schizophrenia.
[13]. Thirdly, because of the cross-sectional design of
this study no direct inferences can be made about the
causal relationship between the determinants found and
the impaired walking capacity. However, the impaired
walking capacity is most likely both the cause and the
consequence of the determinants found. As indicated in
the present study, there might be a negative spiral with
physical inactivity leading to different metabolic compli-
cations, which in turn might affect both health related
muscular fitness and physical activity participation.
Fourthly, also the use of a single field-test to measure
the health related muscular fitness should be considered
as a limitation.
Future research
Future studies should investigate potential neurobiological
mechanisms for the decreased health related muscular fit-
ness observed. Previous research [39] already found
neuromuscular abnormalities either in the muscle biopsy
or macro electromyographic investigations, in almost half
of first-episode and chronic patients. It is however unclear
to which extent these neuromuscular abnormalities, in-
cluding atrophy of the muscle fibres, contribute to impair-
ments in health related muscular fitness. In the same way
it still needs to be explored whether metabolic syndrome
induces peripheral neuropathy [40] and if its associated
loss in peripheral sensation might be associated with
impaired muscle strength. Secondly, more longitudinal re-
search is needed on the effects of duration, side effects,
and dosage of antipsychotic medication on the muscular
fitness of patients with schizophrenia.
Conclusions
The present study demonstrates that in patients with
schizophrenia a reduced walking capacity is associated
with an impaired health related muscular fitness. Older
age, a longer illness duration, a higher BMI and the
current physical activity level are all independent predic-
tors of the health related muscular fitness. Both, the
reduced walking capacity and impaired health related
muscular fitness should be a major focus in daily clinical
practice and future research.
Competing interests
M. De Hert has been a consultant for, received grant/research support and
honoraria from, and been on the speakers/advisory boards of AstraZeneca,
Lundbeck JA, Janssen-Cilag, Eli Lilly, Pfizer, Sanofi-Aventis and Bristol-Myers
Squibb. The other authors reports no financial relationships with commercial
interests.
Authors’ contributions
The study was designed by DV, MDH and MP. All data were collected by DV,
MP and ADH. Statistical analyses were performed by AC and DV. DV, MDH,
and MP wrote the first draft of the paper, and all other co-authors
commented and contributed to the subsequent revisions. All authors have
read and approved the final manuscript.
Author details
1University Psychiatric Centre Catholic University Leuven, Campus
Kortenberg, Kortenberg, Belgium.
2Faculty of Kinesiology and Rehabilitation
Sciences, Catholic University Leuven, Leuven, Belgium.
3CIAFEL - Centre for
Research on Physical Activity, Health and Leisure, University of Porto, Porto,
Portugal.
4Department of Philosophy, Sociology, Education and Applied
Psychology (FISPPA), University of Padua, Padova, Italy.
Received: 17 August 2012 Accepted: 2 January 2013
Published: 3 January 2013
References
1. Strassnig M, Brar JS, Ganguli R: Low cardiorespiratory fitness and physical
functional capacity in obese patients with schizophrenia. Schizophr Res
2011, 126:103–109.
2. Scheewe TW, Takken T, Kahn RS, Cahn W, Backx FJ: Effects of exercise
therapy on cardiorespiratory fitness in schizophrenia patients. Med Sci
Sports Exerc 2012, 44(10):1834–1842.
3. Galletly C: Subjective muscle weakness and hypotonia during clozapine
treatment. Ann Ann Clin Psychiatr 1996, 8(4):189–192.
4. Vancampfort D, Probst M, Sweers K, Maurissen K, Knapen J, De Hert M:
Relationships between obesity, functional exercise capacity, physical
activity participation and physical self perception in people with
schizophrenia. Acta Psychiatr Scand 2011, 123:423–430.
5. Vancampfort D, Sweers K, Probst M, Maurissen K, Knapen J, Minguet P,
De Hert M: The association of metabolic syndrome with physical activity
performance in patients with schizophrenia. Diabetes Metab 2011,
37:318–323.
6. Vancampfort D, Probst M, Scheewe T, Knapen J, De Herdt A, De Hert M:
The functional exercise capacity is correlated with global functioning in
patients with schizophrenia. Acta Psychiatr Scand 2012, 125(5):382–387.
7. Martín-Sierra A, Vancampfort D, Probst M, Bobes J, Maurissen K, Sweers K,
De Schepper E, De Hert M: Walking capacity is associated with health
related quality of life and physical activity level in patients with
schizophrenia: a preliminary report. Actas Esp Psiquiatr 2011,
39(4):211–216.
8. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I,
Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R,
Leucht S: Physical illness in patients with severe mental disorders. I.
Prevalence, impact of medications and disparities in health care.
World Psychiatr 2011, 10:52–77.
9. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller H-J:
Cardiovascular disease and diabetes is people with severe mental illness
position statement from the European Psychiatric Association (EPA),
supported by the European Association for the Study of Diabetes (EASD)
and the European Society of Cardiology (ESC). Eur Psychiatr 2009,
4:412–424.
10. Vancampfort D, Sweers K, Probst M, Mitchell A, Knapen J, Hert D:
Quality assessment of physical activity within clinical practice guidelines
for the prevention and treatment of cardio-metabolic risk factors in
persons with schizophrenia. Community Ment Health J 2011, 47(6):703–710.
11. Vancampfort D, Knapen J, De Hert M, van Winkel R, Deckx S, Maurissen K,
Peuskens J, Simons J, Probst M: Cardiometabolic effects of physical
activity interventions for people with schizophrenia. Phys Ther Rev 2009,
14:388–398.
12. Faulkner G, Cohn T, Remington G: Validation of a physical activity
assessment tool for individuals with schizophrenia. Schizophr Res 2006,
82:225–231.
13. Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M:
A systematic review of correlates of physical activity in patients with
schizophrenia. Acta Psychiatr Scand 2012, 125(5):352–362.
14. Vancampfort D, Knapen J, van Probst M, Winkel R, Deckx S, Maurissen K,
Peuskens J, De Hert M: Considering a frame of reference for physical
Vancampfort et al. BMC Psychiatry 2013, 13:5 Page 7 of 8
http://www.biomedcentral.com/1471-244X/13/5activity research related to the cardiometabolic risk profile in
schizophrenia. Psychiatr Res 2010, 177:271–279.
15. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders. 4th edition. Washington DC: American Psychiatric Association;
2000. text revision.
16. American College of Sports Medicine: ACSM's guidelines for exercise testing
and prescription. 8th edition. Baltimore: Lippincott Williams & Wilkins; 2009.
17. American Thoracic Society: ATS statement: guidelines for the six-minute
walk test. Am J Resp Crit Care Med 2002, 166:111–117.
18. Vancampfort D, Probst M, Sweers K, Maurissen K, Knapen J, De Hert M:
Reliability, minimal detectable changes, practice effects and correlates of
the 6-min walk test in patients with schizophrenia. Psychiatr Res 2011,
187:62–67.
19. Oja P, Tuxworth B: Eurofit for adults, Assessment of health-related fitness.
Strasbourg: Council of Europe-UKK Institute, Tampere; 1995.
20. Vancampfort D, Probst M, Sweers K, Maurissen K, Knapen J, Willems JB,
Heip T, De Hert M: Measuring physical fitness by means of the Eurofit
test battery in patients with schizophrenia: reliability and correlates with
patients' characteristics. Eur Psychiatr 2012, 27(6):416–421.
21. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE,
Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International physical activity
questionnaire: 12-country reliability and validity. Med Sci Sports Exerc
2003, 35:1381–1395.
22. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ,
O'Brien WL, Bassett DR Jr, Schmitz KH, Emplaincourt PO, Jacobs DR Jr,
Leon AS: Compendium of physical activities: an update of activity codes
and MET intensities. Med Sci Sports Exerc 2000, 32:498–504.
23. De Hert M, Van Eyck D, Hanssens L, Peuskens H, Thys E, Wampers M,
Scheen A, Peuskens J: Oral glucose tolerance tests in treated patients
with schizophrenia. Data to support an adaptation of the proposed
guidelines for monitoring of patients on second generation
antipsychotics. Eur Psychiatr 2006, 21(4):224–226.
24. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A,
Peuskens J: Screening for diabetes and other metabolic abnormalities in
patients with schizophrenia and schizoaffective disorder: evaluation of
incidence and screening methods. J Clin Psychiatr 2006, 67(10):1493–1500.
25. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome – a new world-wide
definition, a consensus statement from the International Diabetes
Federation. Diabet Med 2006, 23:469–480.
26. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,
Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes
Federation Task Force on Epidemiology and Prevention, National Heart,
Lung, and Blood Institute, American Heart Association, World Heart
Federation, International Atherosclerosis Society, International Association
for the Study of Obesity: Harmonizing the metabolic syndrome. A joint
interim statement of the International Diabetes Federation Task Force
on Epidemiology and Prevention; National Heart, Lung, and Blood
Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International Association for
the Study of Obesity. Circulation 2009, 120:1640–1645.
27. De Hert M, Bussel J, Lindström E, Abrahams F, Franens C, Peuskens J: PECC,
Psychosis Evaluation tool for Common use by Caregivers. Antwerpen, Belgium:
EPO; 1998.
28. De Hert M, Wampers M, Thys E, Wiselgen I, Lindström E, Peuskens J:
Validation study of PECC (Psychosis Evaluation tool for Common use by
Caregivers): interscale validity and inter-rater reliability. Int J Psychiatr Clin
Pract 2002, 6:135–140.
29. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldesarini RJ:
International consensus study of antipsychotic dosing. Am J Psychiatry
2010, 167(6):686–693.
30. Viertö S, Sainio P, Koskinen S, Perälä J, Saarni SI, Sihvonen M, Lönnqvist J,
Suvisaari J: Mobility limitations in persons with psychotic disorder:
findings from a population-based survey. Soc Psychiatr Psychiatr Epidemiol
2009, 44(4):325–332.
31. Kern PA, Ranganatan S, Li C, Wood L, Ranganatan G: Adipose tissue tumor
necrosis factor and interleukin-6 expression in human obesity and
insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745–E751.
32. Borg J, Edström L, Bjerkenstedt L, Wiesel FA, Farde L, Hagenfeldt L: Muscle
biopsy findings, conduction velocity and refractory period of single
motor nerve fibers in schizophrenia. J Neurol Neurosurg Psychiatry 1987,
50:1655–1664.
33. Vancampfort D, De Hert M, Skjerven LH, Gyllensten AL, Parker A, Mulders N,
Nyboe L, Spencer F, Probst M: International Organization of Physical
Therapy in Mental Health consensus on physical activity within
multidisciplinary rehabilitation programmes for minimising cardio-
metabolic risk in patients with schizophrenia. Disabil Rehabil 2012,
34:1–12.
34. Vancampfort D, Probst M, Helvik Skjaerven L, Catalán-Matamoros D,
Lundvik-Gyllensten A, Gómez-Conesa A, Ijntema R, De Hert M: Systematic
review of the benefits of physical therapy within a multidisciplinary care
approach for people with schizophrenia. Phys Ther 2012, 92(1):11–23.
35. Vanhees L, Lefevre J, Philippaerts R, Martens M, Huygens W, Troosters T,
Beunen G: How to assess physical activity? How to assess physical
fitness? Eur J Cardiovasc Prev Rehabil 2005, 12:102–114.
36. De Bourdeaudhuij I, Sallis JF, Saelens BE: Environmental correlates of
physical Activity in a sample of Belgian adults. Am J Health Prom 2003,
18(1):83–92.
37. De Cocker KA, De Bourdeauduuij IM, Brown WJ, Cardon GM: The effect of a
pedometer-based physical activity intervention on sitting time. Prev Med
2008, 47(2):179–181.
38. World Health Organisation: Highlights on health in Belgium. Office for Health
Promotion. Copenhagen, Denmark: World Health Organisation Regional
Office for Europe; 2004.
39. Flyckt L, Borg J, Borg K, Ansved T, Edman G, Bjerkenstedt L, Wiesel FA:
Muscle biopsy, macro EMG, and clinical characteristics in patients with
schizophrenia. Biol Psychiatry 2000, 47(11):991–999.
40. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL: Diabetic
neuropathy: clinical manifestations and current treatments. Lancet Neurol
2012, 11(6):521–534.
doi:10.1186/1471-244X-13-5
Cite this article as: Vancampfort et al.: An impaired health related
muscular fitness contributes to a reduced walking capacity in patients
with schizophrenia: a cross-sectional study. BMC Psychiatry 2013 13:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vancampfort et al. BMC Psychiatry 2013, 13:5 Page 8 of 8
http://www.biomedcentral.com/1471-244X/13/5